Vinblastine, Sulfate Salt (Alkaban-AQ, Exal, 29060-LE, NSC-49842, Rozevin sulfate, Velban, Velbe, Velsar, Vincaleucoblastine sulfate, Vincaleukoblastine sulfate, VLB sulfate, CAS 143-67-9), >99%

LC Laboratories' Product Number V-7300 - Vinblastine, Sulfate Salt (Alkaban-AQ, Exal, 29060-LE, NSC-49842, Rozevin sulfate, Velban, Velbe, Velsar, Vincaleucoblastine sulfate, Vincaleukoblastine sulfate, VLB sulfate, CAS 143-67-9), >99% - for research use only. Vinblastine is an antimicrotubule drug that has been used to treat various cancers. Interruption of microtubule structure by antimicrotubule drugs results in induction of tumor suppressor gene p53 and inhibitor of cyclin-dependent kinases p21WAF1/CIP1, and phosphorylation of Bcl-2, which lead to apoptosis in cancer cells. Combination chemotherapy with Adriamycin (doxorubicin, please see LC Labs' Cat. No. D-4000, Doxorubicin, Hydrochloride Salt and Cat. No. D-4099, Doxorubicin, Free Base), bleomycin, vinblastine, and dacarbazine (ABVD) is considered the standard of treatment for advanced Hodgkin's lymphoma in North America, providing a good balance of efficacy and toxicity. Vinblastine chemotherapy is the standard treatment for the patients with aggressive systemic Langerhans cell histiocytosis. Vinblastine has potent anti-angiogenic properties at picomolar concentrations. The doses of vinblastine needed to cause antiangiogenesis are significantly lower than cytotoxic doses. Co-targeting of mTOR by temsirolimus (please see LC Labs' Cat. No. T-8040, Temsirolimus) and microtubules by vinblastine in vitro resulted in marked growth inhibition in Huh7 cells and Hep3B cells. The combination of temsirolimus and vinblastine induced a significant and sustained antitumor activity in both Huh7 and Hep3B xenograft models, with significant reduction of tumor vessel density. Weekly vinblastine was demonstrated to be a reasonable alternative to radiation for pediatric patients with low-grade glioma who had failed first-line chemotherapy. The 5-year progression-free survival was shown in this phase II trial to be comparable to results observed with first-line chemotherapy in chemotherapy-naive patients. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin appeared to be a safe, well-tolerated, and effective neoadjuvant chemotherapy regimen for muscle-invasive bladder cancer. Related CAS number: 865-21-4 for the free base.

• Supplier: LC Laboratories
• Product #: V-7300
• Sku #: V-7300_1g